Marc Peeters, MD, PhD, of Antwerp University Hospital, Edegem, Belgium, gives a summary of some of the data presented on panitumumab for metastatic colorectal cancer (mCRC) during the ESMO 2016 meeting in Copenhagen, Denmark. He describes the importance of depth of response, the symptomatic scoring of the patients and evidence presented on the group of patients who should be treated with panitumumab. Treatment strategy is based, not only on the biomarker profile, but also other surrogate markers. According to Dr Peeters, anti-EGFR treatment in wild-type patients who need a rapid response is an excellent option. The sub-analysis performed will allow physicians to guide treatment strategy in some individual cases.
Find his abstracts here: http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf